MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
81.58
-4.31
-5.02%
Opening 14:00 07/13 EDT
OPEN
85.38
PREV CLOSE
85.89
HIGH
85.38
LOW
81.39
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
93.42
52 WEEK LOW
42.09
MARKET CAP
15.98B
P/E (TTM)
-21.7791
1D
5D
1M
3M
1Y
5Y
1D
Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 11h ago
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 13h ago
BridgeBio Pharma Price Target Raised to $120.00/Share From $110.00 by HC Wainwright & Co.
Dow Jones · 13h ago
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120
Benzinga · 13h ago
BridgeBio price target raised to $120 from $110 at H.C. Wainwright
TipRanks · 13h ago
BRIDGEBIO PHARMA, INC. <BBIO.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $120 FROM $110
Reuters · 13h ago
Weekly Report: what happened at BBIO last week (0706-0710)?
Weekly Report · 13h ago
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
Seeking Alpha · 1d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.